About us
- >
- About us >
- Information >
- Announcement
2018-02-02
The IND application of ENERGI-F701 Phase II trial for female pattern hair loss (FPHL) have been noticed by FDA to proceed.
The IND application (137852) of ENERGI-F701 Phase II trial for female pattern hair loss (FPHL) have been noticed by FDA to proceed.
With the approval of U.S. FDA and Taiwan FDA, ENERGI-F701 will launch a phase II trial (NCT03351322) for female pattern hair loss (FPHL) at several medical centers in Taiwan in 2018 Q2.